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A phase III randomised trial of cistplatinum, methotrextate,
cisplatinum + methotrexate and cisplatinum + 5-FU in end stage
squamous carcinoma of the head and neck
The Liverpool Head and Neck Oncology Group
Summary We describe a phase III trial on 200 patients with end stage squamous cell carcinoma of the head
and neck. The patients were randomised to one of four treatment arms: cisplatinum alone, methotrexate alone,
cisplatinum + 5-FU and cisplatinum + methotrexate. There was no significant difference in the response rates,
but the survival of the cisplatinum arm was significantly better than that of the methotrexate arm. The survival
of patients receiving cisplatinum as a single agent was longer than that of patients receiving cisplatinum in
combination with methotrexate or 5-FU, but not significantly so. Nausea/vomiting and anaemia were
significantly more common in the cisplatinum arms than in the methotrexate arm, but the toxicity of
combination regimens was not significantly greater than that of cisplatinum used as a single agent.
Chemotherapy can be used in the treatment of squamous
carcinoma of the head and neck, either as an adjuvant to
surgery or radiotherapy, or for the sole treatment of end
stage disease (that is advanced or recurrent tumours).
Methotrexate was previously regarded as the standard
chemotherapeutic agent for end stage disease and its dosage
and mode of administration have been extensively inves-
tigated in phase II studies. Weekly administration of
40-60 mg m 2 produces the best response rates; higher
dosage and/or more frequent administration does not imp-
rove the rate or duration of response (Muggia et al., 1980).
Cisplatinum has been shown to have antitumour activity in
squamous cell carcinoma of the head and neck (Jacobs et al.,
1980; Wittes et al., 1979). In one of the few randomised trials
undertaken cisplatinum achieved similar response rates
(23.5% and 28.6% respectively) to methotrexate in patients
with recurrent head and neck cancer (Hong et al., 1983).
Several studies using combination chemotherapy suggest
that cisplatinum in combination is superior to cisplatinum
alone. High dose bolus cisplatinum plus 120h continuous
infusion of 5-fluorouracil every 3 weeks achieves a 70%
objective response rate (26% complete responses) in end
stage disease (Decker et al., 1983; Kish et al., 1984). The
importance of the timing is also emphasised. In a randomised
study using equitoxic doses, 5-FU given as a continuous
infusion produced a 72% response rate, but when given as a
bolus injection on days 1 and 8 the response rate dropped to
20% (Kish et al., 1985).
Only two randomised trials have been conducted to assess
the value of cisplatinum as a single agent compared with
cisplatinum in combination. A previous prospective random-
ised trial carried out in this department on end stage patients
compared cisplatinum, bleomycin, cisplatinum + bleomycin
and a control untreated group (Morton et al., 1985).
Although there was no significant difference in the res-
ponse rates of the three treated arms, cisplatinum as a single
agent significantly prolonged the median survival time com-
pared with the other groups. A randomised phase III trial of
cisplatinum with and without methotrexate showed that me-
thotrexate merely increased the toxicity but not the survival
(Jacobs et al., 1983).
We now report a prospective randomised phase III trial
comparing cisplatinum, methotrexate, cisplatinum + 5-fluoro-
uracil and cisplatinum + methotrexate. There was no control
(untreated) arm as we have already shown that cisplatinum
as a single agent significantly prolongs survival in this group
of patients (Morton et al., 1985).
Patients and methods
Patients
Patients with histologically proven end stage squamous cell
carcinoma of the head and neck that was unsuitable for
treatment with surgery or radiotherapy were admitted to this
trial. End stage disease is defined as disease which is too
advanced for treatment by radiotherapy or surgery, or dis-
ease which has recurred after prior radiotherapy and/or
surgery.
Seventy-one patients had received no prior treatment; 129
patients had an untreatable recurrence after prior
radiotherapy and/or surgery. No patient had had prior
chemotherapy. Two hundred such patients were admitted
between May 1984 and November 1987.
The patients' tumour was classified using the site and stage
groupings recommended by the UICC(UICC, 1987). Forty-
five patients with recurrent tumour solely in the neck could
not be assigned a stage group because of the absence of a
primary tumour.
The patients' performance status was classified by Kar-
nofksy's criteria (Karnofsky & Buckenall, 1949). The data
are shown in Table I.
Pretreatment assessment
This included classification of each tumour by site and stage
according to the UICC classification, assessment of the pa-
tient's general condition and Karnofsky performance status,
complete physical examination, routine haematological and
biochemical screening, liver function tests, 24 h creatinine
clearance, chest radiograph, ECG and pure tone audiometry.
Other appropriate investigations were carried out in specific
cases, including CT scan, bone scan, etc. Every patient was
assessed by the same consultant physician, who advised also
on any medical problems encountered during the trial.
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Randomisation
The method of 'intention to treat' was followed, i.e. first all
patients presenting with end stage disease were randomised
to the various treatment groups before assessment of fitness
and obtaining of consent; second no patient was withdrawn
from analysis once he had been randomised, even if he
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Table I Patient details
Cisplatinum Cisplatinum
Cisplatinum Methotrexate + 5-FU + MTX
Site
Mouth 9 14 10 15
Oropharynx 7 8 12 4
Hypopharynx 14 12 7 10
Larynx 13 13 14 13
Others 7 3 7 8
Men 34 36 38 33
Women 16 14 12 17
Age (mean 62 65 59 58
Karnofsky
Median 70 60 70 60
Range 30-90 30-80 20-90 10-90
Previously untreated tumours
Stage III 3 4 3 1
IV 17 1 1 19 14
Recurrent Tumours
Stage II 0 0 1 0
III 3 2 1 2
IV 19 24 12 19
Not classifiable 8 9 14 14
refused, or was unfit, to receive chemotherapy. The patients
were randomised between the four arms by drawing cards
from a bag. Fifty patients were admitted to each arm: cal-
culation showed that this number will detect a three month
prolongation of median survival in this group of patients,
with a type I error of 5% and a type II error of 20%.
Stratification for prognostic factors was not used.
Dosage and administration
Cisplatinum was given by the same method and at the same
dose, in all the three cisplatinum arms: the patients were
prehydrated with 2 litres of normal saline over 16 h, followed
immediately by infusion of cisplatinum at lOOmgm2 plus
12.5 g of mannitol, in 1 litre of normal saline over 8 h.
During the infusion of cisplatinum, patients were given Max-
olon (metoclopramide) at 5 mg kg-' diluted in 500 ml of
normal saline. The cisplatinum infusion was stopped for
15 min every 2 h while the Maxolon infusion was given.
Following the cisplatinum the patients were post-hydrated
with 1 litre of normal saline in 8 h.
Methotrexate was given by intravenous bolus injection, at
a dose of 40 mg m-2. 5-Fluorouracil was given at a dose of
1000 mg m-2 for 4 days as a continuous infusion, each day's
dose being given in 2 litres of normal saline. This infusion
followed the cisplatinum immediately and replaced the post-
hydration.
All of the cisplatinum containing regimens were repeated
at monthly intervals, whereas methotrexate was given every 2
weeks.
Assessment during the trial
During treatment we attempted to see all patients at 2-weekly
intervals to assess the response, the patients' general condi-
tion and any specific symptoms, and to alter any medica-
tions. An FBC and an SMAC (urea, electrolytes and LFTs)
were done on all patients. In addition to this patients receiv-
ing cisplatinum had a chest X-ray, ECG, pure tone audio-
metry and 24 h urinary creatinine clearance before each
course of treatment. If the creatinine clearance fell to be-
tween 50 and 60 ml min-' the dose of cisplatinum was re-
duced to 50 mgm-2. If it fell below 50 ml min ' treatment
was postponed until the creatinine clearance returned to
normal. Treatment was not given when the haematological
indices were unsatisfactory.
Cessation oftreatment
Treatment was discontinued, with the patient's consent, if
there was no evidence of response after three cycles, with the
development of major
quest.
toxicity or at the patient's own re-
Assessment ofresponse
The WHO definition of response was used (Miller et al.,
1981). Accessible lesions of the mouth and nodes in the neck
were measured by calipers. Assessment of laryngeal and
hypopharyngeal lesions was mainly based on clinical
examination. Lesions of the nose, sinus, nasopharynx and ear
were assessed by radiology.
Toxicity
Toxicity was assessed after each course ofchemotherapy. The
data are displayed according to the WHO criteria (Miller et
al., 1981).
Informed consent
Ethical committee approval was obtained for the trial. The
trial, its purpose and side-effects of the chemotherapy were
discussed fully with each patient and his or her relatives.
Follow-up and analysis ofthe data
The exact date of death of those who have died is known
either from personal follow-up or from the Mersey Region
Cancer Registry. The status of the patients who are alive has
been checked within, at most, the past 6 weeks. No patient
has been lost to follow-up.
Qualitative data are displayed in contingency tables and
analysed by X2. Survival is presented by the Kaplan-Meier
method (Kaplan & Meier, 1985). Differences between sur-
vival curves were analysed by the log rank test (Peto et al.,
1976). Prognostic factors were identified by Cox's regression
analysis (Cox, 1972).
Results
Response rate
The response rates are shown in Table II. The response rate
for the whole group was 21.5%, and for treated patients was
27.8%. There was no significant difference in the response
rate between the various arms, either of the whole group
(X29 = 14.42) or of the treated group (X26 = 6.99) The res-
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Table II Response rates
Cis MTX Cis + 5-FU Cis + MTX
Untreated 14 16 11 5
Progressive disease 11 15 14 12
Stable disease 11 13 13 22
Partial response 13 6 9 11
Complete response 1 0 3 0
Survival
Figure 1 shows the survival curves for the four treatment
groups: the cisplatinum arm had a significantly better sur-
vival than the methotrexate arm (X21 = 5.53, P<0.025). The
survival of those receiving cisplatinum in combination with
methotrexate or 5-FU was worse than that of those receiving
cisplatinum alone, but the differences were not significant
(X21 = 1.95, X21 = 0.81 resp.). The survival of those patients
receiving cisplatinum plus methotrexate was only slightly
better than that of those receiving methotrexate alone, and
the difference was not significant (X21 = 0.77).
The median survival for various host, tumour and treat-
ment factors is shown in Table III. Univariate analysis using
the log rank method showed that performance status and
response were significant factors, whereas age, sex, histo-
logical grade, site and previous treatment were not. Analysis
for trend confirmed that the trend of improving survival with
higher rates of Karnofsky status was also highly significant
(X21 = 46.6, P<0.001). Almost all patients were in stage IV
so that analysis for different stage groups was not done.
The data were then submitted to Cox's multivariate regres-
sion analysis, which confirms that only two prognostic fac-
tors had a significant effect on survival: Karnofsky status and
response to chemotherapy (Table IV). The effect of previous
treatment was not quite significant (P = 0.07). This analysis
also confirmed that cisplatinum was better than methotrexate
(z = 2.18, P<0.05), whereas those patients receiving cisp-
latinum plus 5-FU or ciplatinum plus methotrexate did not
do significantly better than those patients receiving
methotrexate alone (z = 1.07, and z = 1.53 respectively).
Toxicity
Nausea, vomiting and renal toxicity caused by the cisp-
latinum containing regimens were the major problems. Mild
nausea and vomiting (WHO 1-2) affected approximately one
third of the patients receiving cisplatinum (Table V) alone or
in combination, and severe nausea and vomiting (WHO 3-4)
in 22%. Methotrexate produced mild nausea and vomiting in
15% of patients and severe vomiting in 10%. The difference
between the methotrexate and cisplatinum arms was
significant, but not between the various cisplatinum arms.
Renal damage sufficient to affect the serum creatinine was
uncommon. Mild (WHO 1-2) effects were seen in 4% of
patients in the cisplatinum arms and in 2% of the methotrex-
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Figure 1 Survival curves of all four groups.
ate patients. There was no significant difference between the
arms. Severe toxicity (WHO 3-4) was not seen (Table VI).
Figure 2 is a histogram showing the percentage of patients
with a creatinine clearance of less than 50 ml min l, for each
agent, related to the number of courses.
Mild anaemia occurred in 28% of patients receiving the
cisplatinum regimens, compared with 9% in the methotrexate
arm. This difference was significant but there was no
difference between the various cisplatinum arms. Only one
patient had severe anaemia (WHO 3-4) (Table VII).
Mild reduction of white cell count (WHO 1-2) affected
8% of patients receiving cisplatinum, and 3% of patients
receiving methotrexate. These differences were not significant.
Severe toxicity (WHO 3-4) was rare (0.5% of the whole
series) (Table VIII).
Mild reduction of platelets (WHO 1-2) was unusual (2.1%
of the whole group) and severe reduction rare (0.2%). There
was no significant difference between the arms (Table IX).
Many other indices were routinely monitored but the num-
ber of patients recording any abnormalities was very small.
Table X summarises these indices.
Table III Univariate analysis of survival
Median survival
No. ofpts (days) X2 (dlf.) P
Hostfactors
Age 0-59 76 143
>60 124 151 0.43 (1) n.s.
Sex Men 141 150
Women 59 148 0.2 (1) n.s.
Karnofsky
0-50 33 28
60 52 96
70 55 200
80-90 60 205 65.23 (3) <0.001
Tumourfactors
Histology
Well diff. 21 89
Mod/poorly diff. 40 164
n.o.s. 139 145 5.71 (3) n.s.
Sites
Mouth 48 160
Naso/oropharynx 37 95
Larynx/
hypopharynx 96 147
Miscellaneous 19 126 0.49 (3) n.s.
Treatmentfactors
No previous RX 72 164 2.72 (1) n.s.
Recurrent tumours 128 131
Response
Prog. dis. 51 79
Stable dis. 59 165
PR/CR 43 388 60.53 (2) <0.001
Table IV Cox's regression analysis
z P
Hostfactors
Age 0.11 n.s.
Sex 0.37 n.s.
Karnofsky status 9.12 <0.0001
Tumourfactors
Histology
Well diff.(compared
with mod/poorly diff.) 1.48 n.s.
Sites (compared with mouth)
Naso/oropharynx 1.79 n.s.
Larynx/hypopharynx 0.10 n.s.
Miscellaneous 1.65 n.s.
Treatmentfactors
Previous treatment 1.85 n.s.
Response 6.93 <0.001314 LIVERPOOL HEAD AND NECK ONCOLOGY GROUP
Table V Nausea and vomiting
WHO grade
No. of
Regime courses 0 1 2 3 4
Cisplatinum 94 43 7 19 25 0
Methotrexate 122 92 14 4 12 0
Cis. + 5-FU 101 50 7 20 23 1
Cis. + MTX 96 36 9 35 9 7
All groups X23 = 36.3, P<0.001. Cisplatinum arms X22 = 2.99, n.s.
Table VI Serum creatinine
No. of
WHO grade
Regime courses 0 1 2 3 4
Cisplatinum 94 87 7 0 0 0
Methotrexate 122 119 3 0 0 0
Cis. + 5-FU 101 98 2 1 0 0
Cis. + MTX 96 93 3 0 0 0
All groups X23 = 4.24, n.s. Cisplatinum arms X22 = 2.89, n.s.
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Figure 2 Histogram of cumulative effect on creatinine clearance.
Table VII Haemoglobin
WHO grade
No. of
Regime courses 0 1 2 3 4
Cisplatinum 94 64 23 7 0 0
Methotrexate 122 110 7 4 0 1
Cis. + 5-FU 101 75 21 4 0 0
Cis. + MTX 96 68 16 12 0 0
All groups X23 = 18.5, P<0.0001. Cisplatinum arm X22 = 2.43, n.s.
Table VIII WBC
No. of
WHO grade
Regime courses 0 1 2 3 4
Cisplatinum 94 89 5 0 0 0
Methotrexate 122 116 3 1 2 0
Cis. + 5-FU 101 89 7 5 0 0
Cis. + MTX 96 90 5 1 0 0
All groups X23 = 4.98, n.s. Cisplatinum arm X22 = 3.96, n.s.
Table IX Platelets
WHO grade
No. of
Regime courses 0 1 2 3 4
Cisplatinum 94 94 0 0 0 0
Methotrexate 122 119 1 1 1 0
Cis. + 5-FU 101 97 1 3 0 0
Cis. + MTX 96 92 2 2 0 0
All groups X23 = 4.08, n.s. Cisplatinum arms X22 = 3.93, n.s.
Table X Treatment regimen
Cisplatinum Methotrexate Cis + S-FU Cis + MTX
Diarrhoea 11 (4) 1 10 (4) 12 (6)
Ulceration 0 2 (1) 2 (2) 0
Cutaneous 0 0 5 (1) 0
Pulmonary 0 1 0 0
Pyrexia 0 1 0 0
Allergy 0 0 1 0
Alopecia 0 0 12 (4) 0
Cardiac 0 0 1 0
Consciousness 0 0 1 0
Neuropathy 0 0 1 0
Urea 11 (4) 3 (3) 6 (2) 9 (4)
Alkaline phosphatase 16 (6) 13 (6) 11 (5) 10 (3)
Bilirubin 3 (1) 0 3 (1) 0
AAT 4 (3) 15 (4) 7 (2) 0
Gamma GT 16 (4) 25 (8) 11 (3) 21 (7)
The figure in parentheses is the number of patients affected.
Discussion
This randomised trial was designed to assess whether treat-
ment of advanced or recurrent head and neck cancer with
cisplatinum alone could produce a survival advantage over
methotrexate alone, and whether the addition of methotrex-
ate or 5-FU to cisplatinum would have any benefit. However,
we have also looked at response rates, and at the toxicity of
the regimens used.
Our response rates are rather poor when compared with
the excellent results of others. In particular our response rate
of 30% to cisplatinum + 5-FU compares badly with that of
Kish et al. (1984), who achieved an overall response rate of
70%, using the same treatment regime. This can perhaps be
explained by the patients' general condition. In Kish et al.'s
study, 80% of patients had a performance status of better
than 70 whereas only 63% in our series were in good condi-
tion.
There was no significant difference in the response rates of
the four groups. However, this is probably a type II error
related to the large number of patients needed to produce a
significant result if response is the sole criterion.
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Our survival analysis showed that cisplatinum as a single
agent was better than methotrexate, and superior also to
cisplatinum in combination with 5-FU or methotrexate, al-
though not significantly so. This is contrary to the present
climate of opinion, which favours a search for combination
regimens. However, no phase III trial has yet demonstrated
that combination regimens achieve a better survival than
single agent cisplatinum.
We have not stratified our patients for prognostic factors.
Many statisticians now agree that the benefits of this method
are not great (Peto et al., 1976), and that multivariate ana-
lysis should be used to identify prognostic factors. Using
Cox's multivariate regression analysis we confirmed the
findings of univariate analysis that the only significant factors
were Karnofsky performance status and response to chemo-
therapy. Other factors, such as age, sex, site of the tumour
and histological grade were not significant prognostic factors.
It seems that every trial/study of chemotherapy in head and
neck cancer produces a different set of significant prognostic
factors (Amer et al., 1980; Bertino et al., 1975; Campbell et
al., 1987; Siodlak et al., 1989; Vogel & Kaplan, 1979; Wolf et
al., 1984), probably because these factors are being con-
founded by other as yet unidentified factors concerned with
cell growth and behaviour, for example tumour DNA con-
tent (ploidy) (Goldsmith et al., 1986) and oncogene expres-
sion (Field et al., 1986).
Methotrexate is clearly a less toxic compound than cis-
platinum, although it was surprising to find no increased
toxicity in combination regimens compared with cisplatinum
alone. The explanation might be that the toxicity categories
in the WHO scale are rather liberal. Even if combination
regimens do not increase toxicity they inevitably increase
cost. This is particularly true of the cisplatinum + 5-FU regi-
men, which requires five extra days in hospital. This adds a
further £1500 (at 1988 prices) to the cost of treatment. In the
complete absence of any survival benefit this extra cost can-
not be justified.
We did not attempt to assess symptom scores in this group
of patients. Most of them had already received extensive
treatment and their quality of life is already so low that
meaningful differences are very hard to detect and measure.
One measure of the quality of life is the proportion of
patients surviving beyond six months. There are two reasons
for this: first, untreated patients rarely survive beyond this
time interval (Morton et al., 1985); and second, six courses of
treatment with the recovery period after each course pro-
duces a period of 6 months when the quality of life is very
low. In order to benefit the patient must survive beyond this
period in reasonable condition, and preferably beyond 1
year. Fifty-two per cent of patients randomised to receive
cisplatinum survived beyond 6 months, whereas 31 % of
patients in the methotrexate arm survived beyond this time.
Only the patient can decide whether this extra survival is
worth the increased morbidity of chemotherapy.
The authors are grateful to the North West Cancer Research Fund
for financial support, and to Mrs B. Cowley and Mrs J. Deeprose for
the typing.
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